A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD)
Status:
Terminated
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine the safety and tolerability of escalating doses of
ARC-AAT and to evaluate the pharmacokinetics of ARC-AAT and the effect of ARC-AAT on
circulating levels of alpha-1 antitrypsin (AAT). The study will consist of two parts, Part A
(conducted in healthy volunteers) and Part B (conducted in AATD patients) at up to 9
escalating dose levels with 6 participants per dose level.
Phase:
Phase 1
Details
Lead Sponsor:
Arrowhead Pharmaceuticals
Treatments:
Alpha 1-Antitrypsin Diphenhydramine Promethazine Protein C Inhibitor